secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0000012208-26-000034
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q1 GAAP net loss $527M ($19.55/share); net sales +1.1% to $592.1M
-------------------------------------------------------------------------

- Net sales $592.1M, up 1.1% YoY; GAAP gross margin 52.3% (flat YoY), non-GAAP gross margin 53.1%.
- GAAP net loss $527.1M (diluted EPS -$19.55) vs prior-year net income $64.0M ($2.29).
- Non-GAAP net income $50.9M ($1.89 diluted EPS); non-GAAP operating income $39.3M, down from $63.0M.
- Operating cash flow $108.1M; free cash flow $78.1M; repurchased ~176k shares during Q1.
- Management cited challenging academic markets and Middle East conflict as headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220826000034/0000012208-26-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220826000034/bio-20260430.htm
  HTML page:      https://secwatch.observer/filing/0000012208-26-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer